Kymera had a big week. This secretive hedge fund bought $172 million of its stock.

Baker Brothers Advisors has been buying up shares of companies in the biopharma and biotech space.

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

European health regulator recommends approval for GSK's twice-yearly asthma drug

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.

Sanofi (SNY) Sees Slight Pessimism From Analysts

Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately.
newscase

Regeneron Shares Face Headwinds Despite Strong Product Portfolio

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Why Wall Street Analysts Are Closely Watching Sanofi (SNY)

Sanofi (NASDAQ: SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has ...
BioSpace

Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...